Lidotral 5 Percent Roll On Gel
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Lidotral 5 Percent Roll On Gel
- Generic name
- LIDOCAINE HYDROCHLORIDE
- Manufacturer
- Puretek Corporation
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 1c4c9ce5-f12d-9c47-e063-6294a90a0b3c
- SPL ID
- 1c4c9ce5-f12d-9c47-e063-6294a90a0b3c
- Version
- 1
- Effective date
- 2024-08-02
- Source export date
- 2026-10-12
- Source partition
- 1
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0001-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/7928c8e8c6256620071a8b7e5b93eb8dfa543649c08d17a01ea02251012ba58c/drug-label-0001-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 01:26:58
| Harmonized routes |
|---|
| TOPICAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| brand name | Lidotral 5 Percent Roll On Gel | openfda.brand_name | |
| generic name | LIDOCAINE HYDROCHLORIDE | openfda.generic_name | |
| manufacturer name | Puretek Corporation | openfda.manufacturer_name | |
| ndc | package | 59088-327-07 | openfda.package_ndc |
| ndc | product | 59088-327 | openfda.product_ndc |
| ndc11 | package | 59088032707 | derived:openfda.package_ndc |
| rxcui | 1010057 | openfda.rxcui | |
| spl id | 1c4c9ce5-f12d-9c47-e063-6294a90a0b3c | id | |
| spl set id | 1c4c9ce5-f12d-9c47-e063-6294a90a0b3c | set_id | |
| unii | V13007Z41A | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS: For external use only. Not for ophthalmic use. PRECAUTIONS: If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. Lidotral® 5% Roll on Gel should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of lidocaine. Carcinogenesis, Mutagenesis and Impairment of Fertility: Studies of lidocaine in animals to evaluate the carcinogenic and mutagenic potential of the effect on fertility have not been conducted. Use in Pregnancy: Teratogenic Effects; Pregnancy Category B. Reproduction studies have been performed for lidocaine in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by lidocaine. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering lidocaine to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place. Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this drug is administered to a nursing mother. Pediatric Use: Dosage in pediatric patients would be reduced commensurate with age, body weight and physical condition.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS: During or immediately after treatment, the skin at the site of treatment may develop erythema or edema or may be the locus of abnormal sensation.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.